Table 1. Baseline characteristics of the study population.
| Total (n = 1536) | ProD (n = 835) | DCV/ASV (n = 265) | SOF-based (n = 218) | GZP/EBV (n = 218) | p-value | |
|---|---|---|---|---|---|---|
| Age (years) | 65.2 ± 10.2 | 64.5 ± 10.2 | 66.9 ± 9.8 | 61.9 ± 9.5 | 63.0 ± 10.1 | <0.001 |
| Male gender, n (%) | 695 (45.2%) | 394 (47.2%) | 106 (40.0%) | 91 (41.7%) | 104 (47.7%) | 0.120 |
| Hemoglobin (g/dl) | 13.4 ± 1.9 | 13.7 ± 1.7 | 13.1 ± 1.9 | 12.6 ± 2.3 | 13.2 ± 1.6 | <0.001 |
| AST (U/L) | 83.0 ± 59.2 | 81.2 ± 51.7 | 82.0 ± 63.9 | 93.5 ± 65.4 | 80.4 ± 71.7 | 0.046 |
| ALT (U/L) | 99.4 ± 107.6 | 92.5 ± 71.4 | 86.8 ± 79.3 | 127.7 ± 223.9 | 78.3 ± 59.1 | <0.001 |
| Total bilirubin (mg/dL) | 1.1 ± 0.9 | 1.0 ± 0.6 | 1.0 ± 0.5 | 1.5 ± 1.8 | 1.0 ± 0.7 | <0.001 |
| HCV-RNA (105 IU/mL) | 2.6 ± 5.5 | 2.5 ± 3.0 | 2.2 ± 4.5 | 4.4 ± 10.4 | 2.0 ± 3.0 | <0.001 |
| Diabetes mellitus, n (%) | 509 (33.1%) | 285 (34.1%) | 81 (30.6%) | 67 (30.7%) | 76 (34.9%) | 0.567 |
| HCV genotype, n (%) | <0.001 | |||||
| 1a | 73 (4.8%) | 56 (6.7%) | 0 | 11 (5.0%) | 6 (2.8%) | |
| 1b | 1347 (87.7%) | 779 (93.9%) | 263 (99.2%) | 95 (43.6%) | 210 (96.3%) | |
| 2 | 107 (7.0%) | 0 | 0 | 107 (49.1%) | 0 | |
| 4 | 1 (0.1%) | 0 | 0 | 0 | 2 (0.9%) | |
| 6 | 2 (0.1%) | 0 | 0 | 3 (1.4%) | 0 | |
| mixed | 3 (0.2%) | 0 | 2 (0.8%) | 2 (1.0%) | 0 | |
| Liver cirrhosis, n (%) | 889 (58.5%) | 494 (59.2%) | 181 (68.3%) | 97 (44.5%) | 127 (58.3%) | <0.001 |
| HCC, n (%) | 217 (14.1%) | 105 (12.6%) | 42 (15.8%) | 31 (14.2%) | 39 (17.9%) | 0.83 |
| Liver transplantation, n (%) | 65 (4.2%) | 7 (0.8%) | 0 | 58 (26.6%) | 0 | <0.001 |
| Creatinine (mg/dl) | 0.91 ± 0.77 | 0.91 ± 0.75 | 0.91 ± 0.63 | 0.89 ± 0.92 | 0.98 ± 0.80 | 0.626 |
| eGFR (mL/min/1.73m2) | 84.8 ± 25.3 | 85.7± 24.7 | 82.3 ± 24.5 | 87.6 ± 25.2 | 81.8 ± 28.0 | 0.026 |
| eGFR category, n (%) | 0.016 | |||||
| G1: >90 mL/min/1.73m2 | 637 (41.5%) | 347 (41.6%) | 105 (39.6%) | 108 (49.5%) | 77 (35.3%) | |
| G2: 60–89 mL/min/1.73m2 | 661 (43.0%) | 377 (45.1%) | 107 (40.4%) | 84 (38.5%) | 93 (42.7%) | |
| G3: 30–59 mL/min/1.73m2 | 206 (13.4%) | 95 (11.4%) | 48 (18.1%) | 23 (10.6%) | 40 (18.3%) | |
| G4: 15–29 mL/min/1.73m2 | 18 (1.2%) | 8 (1.0%) | 3 (1.1%) | 2 (0.9%) | 5 (2.3%) | |
| G5: <15 mL/min/1.73m2 | 14 (0.9%) | 8 (1.0%) | 2 (0.8%) | 1 (0.5%) | 3 (1.4%) | |
Data are expressed as mean ± standard deviation or number (percentage).
Abbreviation: ProD, paritaprevir/ritonavir/ombitasvir/dasabuvir; DCV/ASV, daclatasvir/asunaprevir; SOF, sofosbuvir; GRZ/EBR, grazoprevir/elbasvir; AST, aspartate transaminase; ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; eGFR, estimated glomerular filtration rate